Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma: Differentiated Cell Therapy Platform and Strong Leadership Underpin Buy Rating
- Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories!
- Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
- Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target
- Lyell Immunopharma initiated with a Buy at Needham